{"id":"W2910355860","doi":"10.1136/annrheumdis-2019-eular.1364","title":"AB0768 BASELINE PAIN SEVERITY AS A PREDICTOR OF PAIN IMPROVEMENT FOLLOWING TREATMENT WITH TOFACITINIB IN PSORIATIC ARTHRITIS","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; Gilead Sciences; Sanofi; Amgen; Pfizer; Genentech; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Tofacitinib; Medicine; Psoriatic arthritis; Janus kinase inhibitor; Placebo; Internal medicine; Arthritis; Visual analogue scale; Ankylosing spondylitis; Surgery; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006005607,0.0002823553,0.0007480009,0.0003818222,0.0002577534,0.0005026931,0.0002113178,0.000515152,0.002006664],"category_scores_gemma":[0.002540056,0.0001316751,0.0006269346,0.0005137956,0.0001738194,0.0003621666,0.0001956626,0.001003854,0.0002106039],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002472324,"about_ca_system_score_gemma":0.0003401354,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001982533,"about_ca_topic_score_gemma":0.003440644,"domain_scores_codex":[0.9994915,0.0001393117,0.00006415867,0.00004602097,0.0001364544,0.0001226114],"domain_scores_gemma":[0.9983019,0.0005880217,0.0005745711,0.00003377583,0.0001381665,0.0003636324],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01648938,0.001249479,0.9274171,0.0002404828,0.0007930787,0.0007582661,0.00008642943,0.0005452905,0.004230667,0.00007653222,0.001457099,0.04665621],"study_design_scores_gemma":[0.0002896653,0.002262065,0.9950014,0.00003559492,0.00019502,0.0007000304,0.00007739993,0.0008075948,0.0001754315,0.00004630977,0.0003966262,0.00001288459],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949579,0.002860864,0.00005497613,0.000212601,0.00008908211,0.00001581947,0.0002628343,0.000009728549,0.001536384],"genre_scores_gemma":[0.9986011,0.0005573017,0.00008069375,0.00008825667,0.0001150851,0.00001091726,0.0002906329,0.000001365099,0.0002546168],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002006664,"threshold_uncertainty_score":0.006712914,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01493254061153384,"score_gpt":0.2757741779865268,"score_spread":0.260841637374993,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}